GLP-1 receptor agonists and reduction of liver fat content in NAFLD patients: Just a question of weight loss?

作者信息

Mantovani Alessandro

机构信息

Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Piazzale A. Stefani, 1, Verona 37126, Italy.

出版信息

Dig Liver Dis. 2021 Dec;53(12):1673-1674. doi: 10.1016/j.dld.2021.07.013. Epub 2021 Aug 6.

DOI:10.1016/j.dld.2021.07.013

PMID:34366254

Abstract

摘要

相似文献

GLP-1 receptor agonists and reduction of liver fat content in NAFLD patients: Just a question of weight loss?

Dig Liver Dis. 2021 Dec;53(12):1673-1674. doi: 10.1016/j.dld.2021.07.013. Epub 2021 Aug 6.

Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis.代谢相关脂肪性肝病患者中胰高血糖素样肽-1 受体激动剂疗效的比较：更新的系统评价和荟萃分析。

Front Endocrinol (Lausanne). 2021 Feb 16;11:622589. doi: 10.3389/fendo.2020.622589. eCollection 2020.

GLP-1 receptor agonists in NAFLD.GLP-1 受体激动剂在非酒精性脂肪性肝病中的应用。

Diabetes Metab. 2017 Apr;43 Suppl 1:2S28-2S33. doi: 10.1016/S1262-3636(17)30070-8.

A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.新型抗糖尿病药物治疗非酒精性脂肪性肝病的系统评价。

Ann Pharmacother. 2021 Jan;55(1):65-79. doi: 10.1177/1060028020935105. Epub 2020 Jun 22.

Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials.胰高血糖素样肽1（GLP-1）受体激动剂、吡格列酮和维生素E对非酒精性脂肪性肝病患者肝脏组织学的比较疗效：随机对照试验的系统评价和试点网状Meta分析

Expert Rev Gastroenterol Hepatol. 2023 Mar;17(3):273-282. doi: 10.1080/17474124.2023.2172397. Epub 2023 Feb 6.

Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病合并非酒精性脂肪性肝病的 Meta 分析。

Front Endocrinol (Lausanne). 2021 Apr 9;12:609110. doi: 10.3389/fendo.2021.609110. eCollection 2021.

Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.胰高血糖素样肽-1 类疗法在治疗非酒精性脂肪性肝病中的潜在作用。

World J Gastroenterol. 2014 Jul 21;20(27):9090-7. doi: 10.3748/wjg.v20.i27.9090.

Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease.胰高血糖素样肽-1 受体激动剂在非酒精性脂肪性肝病中的治疗机制和临床疗效。

Int J Mol Sci. 2023 May 26;24(11):9324. doi: 10.3390/ijms24119324.

Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease.肠-肝轴和胰高血糖素样肽-1 受体激动剂在代谢功能障碍相关脂肪性肝病治疗中的作用。

World J Gastroenterol. 2024 Jun 21;30(23):2964-2980. doi: 10.3748/wjg.v30.i23.2964.

Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation.胰高血糖素样肽-1受体激动剂对非酒精性脂肪性肝病和炎症的影响。

World J Gastroenterol. 2014 Oct 28;20(40):14821-30. doi: 10.3748/wjg.v20.i40.14821.

引用本文的文献

Plasma GLP-1 and metabolic dynamics during human liver regeneration and their association with posthepatectomy liver failure.人类肝脏再生过程中的血浆胰高血糖素样肽-1及代谢动力学及其与肝切除术后肝衰竭的关联

Hepatobiliary Surg Nutr. 2025 Feb 1;14(1):49-65. doi: 10.21037/hbsn-24-464. Epub 2025 Jan 17.

Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment.2型糖尿病患者的非酒精性脂肪性肝病：筛查、诊断与治疗

J Clin Med. 2023 Aug 27;12(17):5597. doi: 10.3390/jcm12175597.

Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review.新旧降糖药物治疗非酒精性脂肪性肝病：叙述性综述。

Clin Mol Hepatol. 2022 Oct;28(4):725-738. doi: 10.3350/cmh.2022.0015. Epub 2022 Mar 14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验